<DOC>
	<DOCNO>NCT01038804</DOCNO>
	<brief_summary>The purpose study evaluate survival , response rate , safety tolerability YM155 give combination docetaxel first-line treatment subject human epidermal growth factor 2 non-overexpressing ( HER2 negative ) metastatic breast cancer .</brief_summary>
	<brief_title>A Study YM155 Plus Docetaxel First-Line Treatment Subjects With HER2 Negative Metastatic Breast Cancer</brief_title>
	<detailed_description>This outpatient study . All subject enrol study receive combine regimen YM155 docetaxel docetaxel alone give 21 day cycle . Each subject assess end cycle determine subject continue next cycle . Each subject assign receive YM155 combination docetaxel eligible continue receive combination regimen study one discontinuation criterion meet . If subject discontinues treatment least stable disease ( SD ) subject complete follow-up visit every 12 week 2 year initiate another systemic anti-breast cancer treatment , exhibit progressive disease ( PD ) , death . Each subject contact study site every 12 week survival follow End Treatment Visit . The contact continue death 2 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Histologically cytologicallyproven adenocarcinoma breast HER2 negative . Subjects hormone receptor positive negative status eligible . Additionally , subject triple negative status ( mean estrogen receptor negative , progesterone receptor negative HER2 negative ) eligible No prior chemotherapy regimen metastatic breast cancer Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 1 Baseline Visit The subject 's life expectancy estimate &gt; 12 week Baseline Visit The subject must nonpregnant nonlactating . All sexually active subject childbearing potential must agree use adequate method contraception throughout study period Hypersensitivity docetaxel polysorbate 80 Neuropathy ≥ Grade 2 Baseline Visit Known brain leptomeningeal metastasis assess medical history review physical examination The subject know Human Immunodeficiency Virus ( HIV ) , Hepatitis B surface Antigen hepatitis C antibody</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Metastatic</keyword>
	<keyword>HER2 Negative</keyword>
	<keyword>YM155</keyword>
</DOC>